Chronic myeloid leukemia: Sequencing of TKI therapies

Jorge Cortes, Hagop Kantarjian

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Multiple tyrosine kinase inhibitors (TKIs) are available for managing patients with chronic myeloid leukemia. Although most patients have a favorable outcome with their initial therapy, whether imatinib or a second-generation TKI was used, some will require subsequent use of one or more different TKIs. Such sequencing might be indicated in a reactive way (ie, for patients who have experienced resistance or intolerance to their initial therapy) or in a proactive way (ie, for patients with a somewhat favorable outcome who have not reached an "optimal" outcome). Sequencing of TKIs has become standard practice, and the proper use of sequenced TKIs is likely to optimize outcomes and resource utilization.

Original languageEnglish (US)
Pages (from-to)164-169
Number of pages6
JournalHematology
Volume2016
Issue number1
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Chronic myeloid leukemia: Sequencing of TKI therapies'. Together they form a unique fingerprint.

  • Cite this